Inhaler Devices: The past, the Present, and the Future

Chairperson:

Richard Dekhuijzen¹

Speakers:

Gary Wong,² J. Christian Virchow,³ Henry Chrystyn^4-6

1. Department of Pulmonary Diseases, Radboud University Medical Center, Nijmegen, Netherlands
2. Department of Paediatrics and School of Public Health, Chinese University of Hong Kong, Hong Kong
3. Department of Pneumology/Intensive Care Medicine, Medizinische Klinik 1,
Zentrum für Innere Medizin, Universitätsmedizin Rostock, Rostock, Germany
4. Talmedica Ltd., St Crispin House, Haslingden, UK
5. Faculty of Health and Human Sciences, University of Plymouth, Plymouth, UK
6. Research in Real Life (RiRL), Cambridge, UK

Disclosure:

Richard Dekhuijzen and/or his department have received research grants, unrestricted educational grants, and/or fees for lectures and advisory board meetings from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mundipharma, Novartis, Takeda, Teva Pharmaceuticals, and Zambon. Gary Wong has received research grants from the European Commission, National Natural Science Federation of China, and both the Research Grants Council and Health and Medical Research Fund of Hong Kong. He is also on the advisory board for, and has received industrial grants and travel grants from MSD, GlaxoSmithKline, Pfizer, Takeda, Danone, Nestlé, Mundipharma, AstraZeneca, and Roche. J. Christian Virchow has lectured for and received honoraria from Allergopharma, ALK, Asche-Chiesi, AstraZeneca, Avontec, Bayer, Bencard, Berlin-Chemie, Bionorica, Boehringer Ingelheim, Essex/ScheringPlough, GlaxoSmithKline, Janssen-Cilag, Kyorin, Leti, MEDA, Merck/MSD, Mundipharma, Novartis, Nycomed/ Altana, Pfizer, Revotar, Sandoz-Hexal, Stallergens, Takeda, Teva Pharmaceuticals, UCB/Schwarz-Pharma, and Zydus/Cadila. He has participated in advisory boards for ALK, Asche-Chiesi, Avontec, Berlin-Chemie, Boehringer Ingelheim, Essex/Schering-Plough, GlaxoSmithKline, Janssen-Cilag, MSD/Merck, Mundipharma, Novartis, Revotar, Sandoz-Hexal, UCB/Schwarz-Pharma, and Takeda. He has received grants from Deutsche Forschungsgemeinschaft, Land Mecklenburg-Vorpommern, GlaxoSmithKline, and MSD. Henry Chrystyn has no shares in any pharmaceutical companies. He has received sponsorship, consultancy agreements, and honoraria for presentations from several pharmaceutical companies that market inhaled products, including Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Innovata Biomed, Meda, Mundipharma, Napp Pharmaceuticals, NorPharma, Orion, Sanofi, Teva Pharmaceuticals, Truddell Medical International, UCB, and Zentiva. He has also received research sponsorship from the grant-awarding bodies Engineering and Physical Sciences Research Council and Medical Research Council.

Acknowledgements:

Writing assistance was provided by Dr Sarah Utley, ApotheCom.

Support:

The publication of this article was funded by Teva Pharmaceuticals. The views and opinions expressed are those of the authors and not necessarily of Teva Pharmaceuticals.

Citation:

EMJ Respir. 2015;3[2]:49-54. DOI/10.33590/emjrespir/10314624. https://doi.org/10.33590/emjrespir/10314624.

Keywords:

ERS Congress, European Respiratory Congress

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.